Clinical trials: Usual Interstitial Pneumonia
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Skeletal Muscle Function in Interstitial Lung Disease
Dyspnea (i.e. breathlessness) and exercise intolerance are common symptoms for patients with interstitial lung disease (ILD), yet it is not known why.
- Conditions
- Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Hypersensitivity Pneumonitis, Scleroderma
- Trial name
- NCT03800017
- Testing
- Hyperoxia
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Interstitial Lung Diseases, Idiopathic Pulmonary Fibrosis
A Study of the Natural Progression of Interstitial Lung Disease (ILD)
We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes.
- Conditions
- Interstitial Lung Diseases, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Connective Tissue Disorder
- Trial name
- NCT00470327
- Where
- United States
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Pulmonary Fibroses, Idiopathic
Study to Assess CMR316 in Healthy Volunteers and Patients With Idiopathic Pulmonary Fibrosis
The purpose of this study is to assess the safety, tolerability and pharmacokinetics single and multiple inhaled doses of CMR316 in healthy volunteers and patients with Idiopathic Pulmonary Fibrosis (IPF).
- Trial name
- NCT06589219
- Testing
- CMR316
- Where
- Germany
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Calibr, a division of Scripps Research
Idiopathic Pulmonary Fibrosis
Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC585 in Healthy Male and Female Subjects
The Safety, Tolerability Pharmacokinetic and Food Effect Study of HEC585 in Healthy Male and Female Subjects
- Trial name
- NCT04512170
- Testing
- HEC585
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Idiopathic Pulmonary Fibrosis, Hypersensitivity Pneumonitis
129Xe Gas Exchange Imaging in IPF and cHP: A Reliability Study
This research is a study to test the reliability of Hyperpolarized Xenon MRI (HXe MRI) as a biomarker in interstitial lung disease.
- Trial name
- NCT04677426
- Testing
- Hyperpolarized Xe129
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Idiopathic Pulmonary Fibrosis
Respiratory Muscle Strength in Patients With Idiopathic Pulmonary Fibrosis
Respiratory muscle strength, dyspnea perception, physical activity and quality of life measurements will be performed and groups will be compared in two groups consisting of patients with idiopathic pulmonary fibrosis referred to…
- Trial name
- NCT03588260
- Testing
- no intervention - cross-sectional observational only
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Istanbul Medipol University Hospital
Idiopathic Pulmonary Fibrosis
To Evaluate Drug-drug Interactions Between DWN12088 and Nebivolol or Paroxetine in Healthy Volunteers
An open label, 2-part, one-sequence, 3-period study to evaluate drug-drug interactions between DWN12088 and nebivolol or Paroxetine in healthy volunteers
- Trial name
- NCT04888728
- Testing
- DWN12088, Nebivolol, Paroxetine
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Idiopathic Pulmonary Fibrosis
A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNS-3545 in Healthy Participants
This is a randomized, double-blind, placebo-controlled Phase 1 study of SAD (Part 1) and MAD (Part 2) of orally administered GNS-3545 in healthy adult subjects. The food effect will be assessed in one cohort in Part 1.
- Trial name
- NCT07225296
- Testing
- GNS-3545
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Genosco Inc.
Idiopathic Pulmonary Fibrosis
Comparative Pharmacokinetic(PK) Study of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Subjects Under Fed Conditions
A Randomized, Open-Label, Two-Period, Double-Crossover Comparative Study on the Pharmacokinetics of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Chinese Subjects under Fed Conditions Primary objective…
- Trial name
- NCT06588517
- Testing
- Pirfenidone Modified-Release Tablets, Pirfenidone Tablets
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Overseas Pharmaceuticals, Ltd.
Idiopathic Pulmonary Fibrosis
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects
This clinical trial is the first-in-human study of BBT-877. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses of BBT-877 in healthy adult subjects.
- Trial name
- NCT03830125
- Testing
- BBT-877, Single dose, BBT-877, Multiple doses
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Bridge Biotherapeutics, Inc.
Idiopathic Pulmonary Fibrosis
To Evaluate Drug-drug Interactions Between DWN12088 and Pirfenidone or Nintedanib in Healthy Volunteers
An open label, 2-part, one-sequence, 3-period study to evaluate drug-drug interactions between DWN12088 and Pirfenidone or Nintedanib in healthy volunteers
- Trial name
- NCT04888715
- Testing
- DWN12088, Pirfenidone, Nintedanib
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Idiopathic Pulmonary Fibrosis
Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ARO-MMP7 in normal healthy volunteers (NHVs) and in participants with idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT05537025
- Testing
- ARO-MMP7 Inhalation Solution
- Where
- 19 sites in Denmark, Italy and 4 more
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Healthy
Study of Single and Multiple Doses of PRS-220 Administered by Oral Inhalation in Healthy Subjects
A dose escalating study of PRS-220 administered by oral inhalation in healthy subjects
- Trial name
- NCT05473533
- Testing
- PRS-220
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Pieris Australia Pty Ltd
Idiopathic Pulmonary Fibrosis
A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of PMG1015
This is a Phase 1A, first in human, randomized, double-blinded, placebo-controlled, dose escalation study of PMG1015 in healthy adult volunteers.
- Trial name
- NCT05022771
- Testing
- PMG1015 Dose 1, PMG1015 Dose 2, PMG1015 Dose 3
- Where
- Australia
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Pulmongene Ltd.
Lung; Disease, Interstitial, With Fibrosis, Alveolitis, Extrinsic Allergic
BPF Genetics of ILD Study
The investigators aim to examine the genetic determinants of interstitial lung disease in a cohort of subjects with regular exposure to pigeons, a known cause of one form of interstitial lung disease known as hypersensitivity…
- Conditions
- Lung; Disease, Interstitial, With Fibrosis, Alveolitis, Extrinsic Allergic, Bird Fancier's Lung, Idiopathic Interstitial Pneumonias
- Trial name
- BPF GILD (NCT03747627)
- Testing
- Genetic profiling
- Where
- 2 sites in United Kingdom
- Volunteers
- 475 people, healthy volunteers welcome
- Sponsor
- University of Dundee
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Toward Self-management in ILD
Treating and caring for people with long term conditions accounts for a substantial proportion of health care resources. Self-management is advocated as a mechanism that can empower service users with long term conditions to…
- Conditions
- Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Connective Tissue Related ILD, Chronic Hypersensitivity Pneumonitis
- Trial name
- NCT03300583
- Testing
- Focus groups, Semi-structured interviews
- Where
- 2 sites in United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Kingston University
Idiopathic Pulmonary Fibrosis
Home Monitoring in Idiopathic Pulmonary Fibrosis; Improving Use of Anti-fibrotic Medication and Quality of Life
In this study it will be investigate whether a home monitoring program improves disease-specific health-related quality of life (HRQOL) for patients with idiopathic pulmonary fibrosis (IPF) through appropriate medication use and…
- Trial name
- NCT03420235
- Testing
- Home monitoring program
- Where
- Netherlands
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Erasmus Medical Center
Idiopathic Pulmonary Fibrosis (IPF)
TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis
This is a Phase 1, 4-part, randomized, double-blinded, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TD-1058 inhaled solution.
- Trial name
- NCT04589260
- Testing
- TD-1058
- Where
- United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Interstitial Lung Diseases
Interstitial Lung Disease: A Study From Infancy to Elderly Including Relatives
The concerned patients are children and adults suffering from idiopathic interstitial pneumonias, other chronic fibrosing interstitial pneumonias with a progressive phenotype, and interstitial pneumonia associated with…
- Trial name
- RaDiCo-ILD 2 (NCT06036719)
- Where
- France
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Idiopathic Pulmonary Fibrosis
First Time in Human (FTIH) Study of GSK3008348 in Healthy Volunteers and Idiopathic Pulmonary Fibrosis Patients
GSK3008348 is an investigational drug, being developed by GlaxoSmithKline Research and Development Limited (the Sponsor, a pharmaceutical company based in the UK) for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
- Trial name
- NCT02612051
- Testing
- GSK3008348 Nebuliser solution, GSK26346763: ([18F]-FBA-A20FMDV2) IV infusion
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline